Adipositas - Ursachen, Folgeerkrankungen, Therapie 2024; 18(04): 201-205
DOI: 10.1055/a-2415-3465
Review

Adipositas in der gynäkologischen Onkologie

Obesity in Gynaecological Oncology
Laura Weydandt
1   Universitätsklinikum Leipzig, Klinik und Poliklinik für Frauenheilkunde, Leipzig, Deutschland
,
Bahriye Aktas
1   Universitätsklinikum Leipzig, Klinik und Poliklinik für Frauenheilkunde, Leipzig, Deutschland
› Author Affiliations

Abstract

Die Adipositas ist eine moderne Zivilisationskrankheit, deren Häufigkeit steigt und die mit zahlreichen Risiken für Folgeerkrankungen verbunden ist. In der gynäkologischen Onkologie ist sie vor allem mit einem erhöhten Risiko für ein Endometrium- und für eine postmenopausale Erkrankung an einem Mammakarzinom verbunden. Ursachen dafür können eine gesteigerte Östrogensekretion, eine Hyperinsulinämie und eine chronische Entzündung sein. Die Datenlage bezüglich einer Risikoerhöhung für andere gynäkologischer Entitäten wie dem Zervix-, Ovar- und Vulvakarzinom ist weiterhin unklar. Hinsichtlich des Einsatzes einer möglichen Chemotherapie gibt es immer wieder Unklarheiten bezüglich der korrekten Dosierung und möglicher Toxizitäten bei adipösen Patientinnen. Die internationale ASCO- (American Society of Clinical Oncology) Leitlinie empfiehlt, die volle, gewichtsabhängige Dosierung, im kurativen Setting einzusetzen. Eine operative Therapie sollte, wenn technisch möglich und onkologisch sicher, minimal-invasiv durchgeführt werden. Hierbei wird für adipöse Patientinnen vor allem das Risiko für frühe postoperative Komplikationen, im Gegensatz zu offenen Operationen, gesenkt.

Abstract

Obesity is a modern disease that is becoming increasingly common and is associated with numerous risks for secondary diseases. In gynecological oncology, obesity is primarily associated with an increased risk for endometrial cancer and postmenopausal breast cancer. This may be due to increased estrogen secretion, hyperinsulinemia and chronic inflammation. The data regarding an increased risk for other gynecological entities such as cervical, ovarian and vulvar cancer is still unclear. With regard to the use of chemotherapy, there are still uncertainties about the correct dosage and possible toxicities in obese patients. The ASCO (American Society of Clinical Oncology) guideline recommends using the full, weight-dependent dosage in the curative setting. If possible and oncological safe, surgical treatment should be done laparoscopically. Above all, this reduces the risk for early complications for obese patients, in contrast to open surgery.



Publication History

Article published online:
13 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Agnew HJ, Kitson SJ, Crosbie EJ. Gynecological malignancies and obesity. Best Pract Res Clin Obstet Gynaecol 2023; 88: 102337
  • 2 Anonymous Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 2012; 9: e1001200
  • 3 Bouwman F, Smits A, Lopes A. et al. The impact of BMI on surgical complications and outcomes in endometrial cancer surgery – an institutional study and systematic review of the literature. Gynecol Oncol 2015; 139: 369-376
  • 4 Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591
  • 5 Clarke BA, Cooper K. Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol 2012; 19: 231-238
  • 6 Crosbie EJ, Kitson SJ, Mcalpine JN. et al. Endometrial cancer. Lancet 2022; 399: 1412-1428
  • 7 Griggs JJ, Mangu PB, Anderson H. et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30: 1553-1561
  • 8 Güzel AB, Khatib G, Küçükgöz Güleç Ü. et al. The impact of morbid obesity on survival of endometrial cancer. Turk J Obstet Gynecol 2020; 17: 209-214
  • 9 Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol 2015; 138: 201-206
  • 10 Iges-Institut. Anteil der schwer adipösen Erwachsenen. Weissbuch Adipositas; 2016
  • 11 Kawai E, Benoit L, Hotton J. et al. Impact of obesity on surgical and oncologic outcomes in patients with endometrial cancer treated with a robotic approach. J Obstet Gynaecol Res 2021; 47: 128-136
  • 12 Klapdor R, Hillemanns P, Wölber L. et al. Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. Int J Gynecol Cancer 2020; 30: 920-926
  • 13 Kölbl H, Bartl T. Obesity in Gynecologic Oncology. Geburtshilfe Frauenheilkd 2020; 80: 1205-1211
  • 14 Lacey JV, Swanson CA, Brinton LA. et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer 2003; 98: 814-821
  • 15 Mccullough ML, Patel AV, Patel R. et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008; 17: 73-79
  • 16 Mili N, Paschou SA, Goulis DG. et al. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine 2021; 74: 478-497
  • 17 Ogden CL, Carroll MD, Kit BK. et al. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012; 82: 1-8
  • 18 Olsen CM, Nagle CM, Whiteman DC. et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 2013; 20: 251-262
  • 19 Poorolajal J, Jenabi E. The association between BMI and cervical cancer risk: a meta-analysis. Eur J Cancer Prev 2016; 25: 232-238
  • 20 Ri M, Aikou S, Seto Y. Obesity as a surgical risk factor. Ann Gastroenterol Surg 2018; 2: 13-21
  • 21 Sand FL, Urbute A, Ring LL. et al The influence of overweight and obesity on participation in cervical cancer screening: A systematic review and meta-analysis. Prev Med 2023; 172: 107519
  • 22 Schouten LJ, Rivera C, Hunter DJ. et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 2008; 17: 902-912
  • 23 Singh A, Hardin BI, Singh D. et al. Epidemiologic and Etiologic Considerations of Obesity. Stat Pearls: Florida. 2020
  • 24 Smits A, Lopes A, Das N. et al. Surgical morbidity and clinical outcomes in ovarian cancer - the role of obesity. Bjog 2016; 123: 300-308
  • 25 Stephan JM, Goodheart MJ, Mcdonald M. et al. Robotic surgery in supermorbidly obese patients with endometrial cancer. Am J Obstet Gynecol 2015; 213: 49.e41-49.e48
  • 26 Ward ZJ, Bleich SN, Cradock AL. et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med 2019; 381: 2440-2450
  • 27 Wise MR, Jordan V, Lagas A. et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am J Obstet Gynecol 2016; 214: 689.e681-689.e617